Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide–bor...

Descripción completa

Detalles Bibliográficos
Autores principales: Theodorakakou, Foteini, Dimopoulos, Meletios A., Kastritis, Efstathios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613887/
https://www.ncbi.nlm.nih.gov/pubmed/34840708
http://dx.doi.org/10.1177/20406207211058334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613887/
https://www.ncbi.nlm.nih.gov/pubmed/34840708
http://dx.doi.org/10.1177/20406207211058334

Ejemplares similares